Abstract: The present invention relates to a compound of the formula [1′] 1

Abstract: This invention relates aryl substituted pyridines of Formula I: 1

Abstract: The present invention relates to mixtures of avermectins, 22,23-dihydroavermectin B1 (ivermectin) and milbemycins from the class of the macrocyclic lactones with agonists or antagonists of the nicotinergic acetylcholine receptors of insects, if appropriate in the presence of other active compounds and diluents or excipients.

Abstract: As disclosed herein, the present invention provides a compound having the structural formula 1

Abstract: Combination therapy comprising RXR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.

Abstract: This invention is to provide remedies for ischemic stroke which contain as an active ingredient a compound having mGluR1 antagonism, pharmaceutical compositions which are remedies for ischemic stroke at the acute stage, pharmaceutical compositions which contain as an active ingredient a compound having selective mGluR1 antagonism, and pharmaceutical compositions wherein the compound having selective mGluR1 antagonism is 6-amino-N-cyclohexyl-N,3 -dimethylthiazolo[3,2-a]benzoimidazole-2-carboxamide dihydrochloride.

Abstract: The present invention relates to acylated indanyl amines according to the general formula (I) 1

Abstract: The invention provides compounds of the formula I 1

Abstract: The present invention provides a method of treating or preventing neutrophil chemotaxis. Specifically, the present invention provides a method of treating or preventing neutrophil migration by administering to a patient a MEK inhibitor.

Abstract: The present invention provides a fungicidal composition characterized by containing as active ingredients

Abstract: The present invention is directed to novel indazolyl-substituted pyrroline compounds of Formula (I): 1

Abstract: The invention provides the use of a compound formula (I) wherein R1 and R2 independently represent H or C1-C6 alkyl, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of: dermatological disorders; peripheral neuropathies; arthritis; gastrointestinal or urogenital disease; headache associated with substances or their withdrawal; tension headache; pediatric migraine; post-traumatic dysautonomic cephalgia; orofacial pain; allergic or chronic obstructive airways diseases, glaucoma or ocular inflammation; or prophylaxis of migraine 1

Abstract: The subject invention pertains to pharmaceutical compositions, articles of manufacture, and methods useful for treatment of neurological conditions related to, or which can be affected by, modulation of glutamate receptor (GluR) activity. The treatment can be either prophylactic in nature or to alleviate symptoms of such neurological conditions. The pharmaceutical compositions of the subject invention include an aromatic amino acid (AAA), an analog or isomer of an AAA, or combinatins thereof, and a pharmaceutically acceptable carrier or diluent. Methods of the subject invention involve parenterally administering to a patient at least one AAA, an analog or isomer of an AAA, or combinations thereof.

Abstract: Compounds are described that bind to tubulin causing tubulin depolymerization and inhibiting tubulin polymerization. The compounds of the invention are therapeutically effective to inhibit cellular proliferation, for example, as effective anti-cancer agents. The compounds can also induce cytotoxicity in cells such as leukemia cells. The chemical structure of the compounds includes a furan, thiophene, thiazole, oxazole, or imidazole group at one end of the molecule (head) and a hydrophobic, aliphatic chain at the other end of the molecule (tail).

Abstract: A method for inhibiting the formation of osteoclasts comprising administering a therapeutically effective amount of a statin to a mammal in need thereof as well as pharmaceutical compositions, kits for containing such compositions comprising a statin or a method of treating or preventing a disease state selected from the group consisting of: osteoporosis, Paget's disease, osteolysis, hypercalcemia of malignancy, osteogenesis imperfecta, osteoarthritis, alveolar bone loss, side effects of immunosuppressive therapy, and side effects of chronic glucocorticoid use by inhibiting the formation of osteoclasts comprising administering a therapeutically effective amount of a statin to a mammal in need thereof.

Abstract: Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.

Abstract: Discovery of a neuroprotective effect in vivo of Achyrocline satureoides (“Marcela”) extracts and of liposomal preparations of natural and semi-synthetic flavonoids structurally related to quercetin. This effect is obtained mainly through antiapoptotic mechanisms, complementary and different of the antioxidant actions of flavonoids. The compounds will be beneficial for the prevention and treatment of stroke and neurodegenerative and aging brain lesions. These benefits will be obtained by the administration of compositions comprising one or various compounds of general formula 1. The liposomal preparation of these compounds increases neuroprotection and will be the preferred application.

Abstract: A composition for removal of lice ova or nits from the hair of human subjects comprises about 1-50% by weight of dimethylisosorbide (DMI) in an aqueous vehicle having a neutral to acidic pH. The composition is preferably in the form of a gel or a liquid shampoo, the shampoo preferably including an active pediculicidal or ovicidal agent. A method of removing lice ova from human hair comprises the application of the novel composition to the hair and subsequent removal thereof, e.g., by rinsing with water. Any unremoved ova can be physically dislodged by combing. The composition can also be included with a fine tooth nit comb in a kit for removal of lice ova from human hair.

Abstract: The present invention relates to drugs and, particularly, to anticancer agents.

Abstract: The present invention relates to the use of peroxometallic compounds, such peroxovanadium compounds, to prevent angiogenesis, restenosis and the production of endothelins, as immunomodulators and as antitumorigenic agents. Peroxometallic compounds are preferred since they are more potent, and less toxic, than their “oxo” counterparts, as exemplified by specific peroxovanadium compounds. Anti-angiogenic activity was verified in vitro against human umbilical vascular endothelial cells (HUVECs) as well as ex ovo using the chicken chorioallantoic assay membrane and in the rat aortic ring model and a Matrigel assay in vivo. Peroxovanadium compounds also decrease basal levels and inhibit the increase in plasma endothelins occurring following insulin induction in rats.

Abstract: A pharmaceutical composition comprising a pharmaceutically active agent and a salt of said pharmaceutically active agent with the proviso that said composition does not contain hydrolyzed cellulose, wherein said pharmaceutical active agent is a weak acid or weak base. The present invention is also directed to a new ibuprofen form having, when potassium is present in said form as a counter ion, an IR peak at 1706 cm−1 shifted and broadened in absorbance relative to racemic ibuprofen free acid, the form's characteristic absorbance profile from 1000 to 650 cm−1 and broadened in absorbance relative to racemic ibuprofen free acid, the form's characteristic absorbance profile from 1000 to 650 cm−1 and D-spacings of 21.1, 7.1, and 3.4 Å by X-ray diffraction.

Abstract: The invention provides for methods of monitoring the proliferation of cultured prostate cancer cells in the presence of omega-3 fatty acids, methods of treating an individual with prostate cancer or at risk of developing prostate cancer, and methods of reducing the risk of recurrence of prostate cancer in an individual who had previously been treated for prostate cancer. Methods of the invention further include treating an individual with benign prostatic hyperplasia (BPH) with omega-3 fatty acids as well as methods of screening for compounds that inhibit the proliferation of prostate cancer cells. The invention provides for compositions and articles of manufacture containing omega-3 fatty acids in particular formulations, and omega-3 fatty acids with a second compound that also exerts an effect on the androgen receptor.

Abstract: A pharmaceutical composition containing substantially pure and stable gabapentin are disclosed wherein gabapentin has a pH of between 6.8 to 7.3.

Abstract: A variety of retinoid compounds well suited for preventively or curatively treating a bacterial colonization infesting/infecting an individual subject exhibit pronounced antibacterial activity, notably pronounced antibacterial activity in respect of the bacterium Staphylococcus aureus, and are also well suited for the cleansing/deodorizing of human skin.

Abstract: Derivatives of N-deacetyl-thiocolchicine or of the isoster thereof of formula (I) 1

Abstract: The present invention is directed to forms II, III, V, VI, VII, VIII, IX and X of sertraline hydrochloride and novel methods for their preparation. According to the present invention, sertraline hydrochloride polymorph II may be produced by slurrying sertraline hydrochloride polymorph VI in aprotic organic solvent. Sertraline hydrochloride polymorphic form III may be produced by heating sertraline hydrochloride polymorphs V and VI. Sertraline hydrochloride forms V and VI may be produced from either sertraline hydrochloride or sertraline base by crystallization. Sertraline hydrochloride Form VII may be produced by suspending sertraline chloride polymorph V in water, followed by filtration. Sertraline hydrochloride Forms VIII and IX may be produced by suspending sertraline base in water followed by acidification and filtration. Sertraline hydrochloride Form X may be produced by suspending sertraline hydrochloride in benzyl alcohol with heating, followed by filtration.

Abstract: In various aspects, the invention provides methods for treating ocular inflammation using copper chelating compounds, such as compounds other than D-penicillamine. In some embodiments, such compounds may be polyamines, such as triethylenetetramine or tetraethylenepentamine. For example, the present invention provides methods for treating inflammation secondary to ocular laser therapy.

Abstract: The invention provides for methods of monitoring the proliferation of cultured prostate cancer cells in the presence of POH, methods of treating an individual with prostate cancer or at risk of developing prostate cancer, and methods of reducing the risk of recurrence of prostate cancer in an individual who had previously been treated for prostate cancer. Methods of the invention further include treating an individual with benign prostatic hyperplasia (BPH) with POH as well as methods of screening for compounds that inhibit the proliferation of prostate cancer cells. The invention provides for compositions and articles of manufacture containing POH in particular formulations, and POH with a second compound that also exerts an effect on the androgen receptor.

Abstract: A water-based ink for ink-jet printing, comprising colored particles containing: (a) a core particle having a colorant; and (b) a shell having a resin and encapsulating the core particle, wherein the resin comprises a monomer unit having a hydroxyl group in an amount of 0.1 to 50 weight % based on the total weight of the shell.

Abstract: A method for removing CO2 from a gas stream, including methane and CO2. The method includes contacting a gas stream with an aqueous stream, so that at least a portion of the CO2 in the gas stream is dissolved into the aqueous stream, thereby creating a CO2-depleted gas stream, having an enriched methane concentration, and a CO2-enriched aqueous stream. The CO2-enriched aqueous stream is separated from the gas stream. Finally, the CO2-enriched aqueous stream is disposed of in at least one of a marine environment, a terrestrial formation or combination thereof.

Abstract: A process for removing CO2 from a CO2-containing gas. The process includes scrubbing CO2 from a CO2-containing gas using an aqueous phase liquid forming a CO2-enriched aqueous phase. The CO2-enriched aqueous phase is then disposed of in at least one of a marine environment, a terrestrial formation or combination thereof.

Abstract: It has been found that non-chlorinated pentafluorobutane blowing agents may be used alone or in combination with water in flexible integral skin foams. For example, foams prepared using 1,1,1,3,3-pentafluorobutane (HFC 365mfc) alone or in combination with water or other non-cholorinated hydrocarbons such as heptafluoropropane exhibit improved physical characteristics, such as resistance to abrasion and cracking, on flex comparable to conventional chlorinated fluorocarbon blown foam.

Abstract: Foamable modified polystyrene resin particles which are foamable modified polystyrene resin particles (d) comprising modified polystyrene resin particles (c) containing a blowing agent (e); the modified polystyrene resin particles (c) comprising a polystyrene resin and rubber polymer particles (b) being dispersed in the resin, wherein the rubber polymer particles (b) are dispersed uniformly throughout a continuous phase of the polystyrene resin or in a state of a density of the particles (b) being higher in a center portion of the resin particle than in a surface layer portion thereof, and the modified polystyrene resin particles (c) are modified polystyrene resin particles prepared by impregnating a monomer mixture consisting essentially of a styrene monomer and a conjugated diene monomer and comprising the styrene monomer in a larger amount than the conjugated diene monomer, into polystyrene resin particles (a) and carrying out copolymerization.

Abstract: The invention provides polymeric optical materials that can be cured in air and have low optical loss in both the C-band and the L-band of the telecommunications spectrum. The polymeric materials are made by the free radical polymerization of an at least difunctional thiol compound with an at least difunctional ethylenically unsaturated compound wherein at least one of the thiol compound and the ethylenically unsaturated compound is at least partially halogenated. The compositions of this invention may be used to fabricate planar optical waveguides with low loss and low birefringence.

Abstract: In accordance with the present invention, there are provided novel thermosetting resin compositions which do not require solvent to provide a system having suitable viscosity for convenient handling. Invention compositions have the benefit of undergoing rapid cure. The resulting thermosets are stable to elevated temperatures, are highly flexible, have low moisture uptake and are consequently useful in a variety of applictions, e.g., in adhesive applications since they display good adhesion to both the substrate and the device attached thereto.

Abstract: Ocular implants composed of homopolymers containing stable elasticity inducing crosslinkers which contain rigid chemical groups disposed between at least two polymerizable ethyleneically unsaturated chemical groups are disclosed. These ocular implants are stable, elastic, soft, optically clear, have high refractive index and low-tack surfaces.

Abstract: One embodiment of the invention provides a dental cement composition which includes (a) an acid group-having polymerizable monomer, (b) a polyalkenoic acid, (c) an ion-leachable glass filler, (d) a polymerizable monomer not having an acid group, (e) water, (f) a peroxide, (g) a salt of an aromatic sulfinic acid, and (h) an aromatic secondary amine and/or an aromatic tertiary amine.

Abstract: A dental adhesive composition for bonding dental restoratives to dentin and enamel provides a one-part self-etching, self-priming dental adhesive composition having hydrolysis stable polymerizable acidic adhesive monomers.

Abstract: This invention relates to an organic foundry binder containing an alkyl resorcinol, or preferably a readily available mixture of alkyl resorcinols, and derivatives thereof. Preferably, the organic foundry binder is a furan binder. Foundry mixes are prepared by mixing the binder with a foundry aggregate. Foundry shapes (molds and cores) are prepared by shaping the mix and allowing it to cure to form a workable foundry shape. The invention also relates to the preparation of metal castings using the foundry shapes and the metal castings prepared with the foundry shapes.

Abstract: A brake pad lining composition is provided that includes a friction modifier for adjusting a coefficient of friction of the brake pad lining and a strengthener for providing structural integrity. The composition also includes a fly ash filler for increasing the volume of the brake pad lining. A binder, such as phenolic resin, holds the friction modifier, the strengthener, and the filler together. By utilizing fly ash as a filler, the cost of the brake pad may be significantly reduced. Design of the brake pad lining may be simplified and the filler used more effectively by achieving a desired ratio of fly ash and binder, and then adding the friction modifier and strengthener to systematically adjust the brake lining properties.

Abstract: A non-erasable ink composition suitable for use in writing instruments is described comprising an isocyanate free thermoplastic polyurethane resin, a colorant and an organic solvent. The ink composition may also include a second resin, plasticizers, antioxidants, corrosion inhibitors, lubricants, chemical dispersants, and surfactants. The inks of the present invention exhibit a smooth writing performance and non-seepage.

Abstract: A fluorescent ink composition suitable for use in free ink writing instruments is described comprising a fluorescent pigment dispersion, a water miscible organic solvent, a defoaming agent, and water. The ink composition may also include additives such as an additive to increase cap-off stability. The ink composition flows smoothly and continuously from a free ink writing instrument.

Abstract: The present invention relates to aqueous, pigment-based ink compositions for use in ink jet printers. These compositions comprise a carrier medium, an insoluble pigment, and a polymer produced by reacting a mixture of styrene, acrylic acid, and butyl acrylate in a polymerization reaction. The ink compositions are characterized by their water resistance and accent marker resistance properties, while also achieving excellent print quality, jetting properties, storage stability, reliability, and dying times.

Abstract: A thiophene compound represented by formula (I): 1

Abstract: The present invention provides a coating type reinforcement composition of sheet metal which can be applied under warming for ensuring satisfactory levels of tensile rigidity and resistance to dent of a thin sheet metal mainly due to weight reduction of an automobile body, or for collision safety, and which improve a bending strength and a rigidity of the sheet metal without causing a distortion to the sheet metal.

Abstract: A method of preparing a cohesive product having a density of from 250 kg/m3 to 900 kg/m3 from a low density feedstock, such as a milled thermoset resin foam, includes the steps of providing the feedstock in the form of substantially dry finely divided particles or fibres, mixing the feedstock with a suitable amount of a thermosetting resin in finely divided dry powder form and a suitable amount of a hydraulic binder in finely divided dry powder form, to give a dry starting material having a compression ratio of at least 2:1, and forming the starting material into a mat and pressing the mat at suitable conditions of temperature and pressure to compress the mat and to cause the thermosetting resin to set to form the cohesive product. Thereafter, there may be provided to the cohesive product water in an amount sufficient for the hydration of the hydraulic binder so that the hydraulic binder sets to form a finished product.

Abstract: An absorbent cellulose material having an application of superabsorbent polymer adhered to the cellulose material. In particular, the cellulose material has an application of pre-superabsorbent polymer adhered to the material, wherein an aqueous solution of pre-superabsorbent polymer is applied to the cellulose material and converted to superabsorbent polymer upon subjected to heat for a sufficient time. The absorbent cellulose material has a fluid retention of greater then 2g/g.

Abstract: The present invention provides a composition for preparing substances having nano-pores, said composition comprising cyclodextrin derivative, thermo-stable organic or inorganic matrix precursor, and solvent for dissolving said two solid components. There is also provided an interlayer insulating film having evenly distributed nano-pores with a diameter less than 50 Å, which is required for semiconductor devices.

Abstract: The present invention relates to aqueous, pigment-based ink compositions for use in ink jet printers. These compositions comprise a carrier medium, an insoluble pigment, and a polymer produced by polymerizing at least one ethylenically-unsaturated monomer with at least one glycol ester monomer. The ink compositions are characterized by their water resistance and accent marker resistance properties, while also achieving excellent print quality, jetting properties, storage stability, reliability, and dying times.

Abstract: The invention relates to a white, biaxially oriented film which comprises a crystallizable thermoplastic as main component and is characterized by further comprising at least one UV-stabilizer, at least one white pigment and at least one flame-proofing agent, which is soluble in the thermoplastic and introduced directly, during the film production, by masterbatch technology, whereby the masterbatch is pre-conditioned by gradual heating under reduced pressure and with stirring.